- Gene editor Scribe starts second-half IPO spree with $129M listingA 9-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half. Scribe Therapeutics priced its $128.7 millionEndpoints · 5h ago↗ source
- STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptidesThe panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.STAT · 10h ago↗ source
- FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157An FDA advisory committee voted Thursday to recommend expanding access to a popular peptide used by health and wellness enthusiasts for repairing muscles and healing injuries. The recommendation se…